| Assessment Status | Rapid Review complete |
| HTA ID | 24016 |
| Drug | Dantrolene sodium hemiheptahydrate |
| Brand | Agilus® |
| Indication | In combination with adequate support measures, dantrolene sodium hemiheptahydrate is indicated for the treatment of malignant hyperthermia in adults and children of all ages. |
| Assessment Process | |
| Rapid review commissioned | 20/05/2024 |
| Rapid review completed | 27/06/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that dantrolene sodium hemiheptahydrate (Agilus®) not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
